Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Amgen Inc. (AMGN) -- Ignore unavailable to you. Want to Upgrade?

To: DewDiligence_on_SI who wrote (1294)	9/27/2006 4:05:31 PM
From: tuck	Read Replies (1) \| Respond to of 1906

This was stamped 3:52PM; AMGN up to $72.25: >>WASHINGTON, Sept 27 (Reuters) - The U.S. Food and Drug Administration said on Wednesday it had approved Amgen Inc.'s (AMGN.O: Quote, Profile, Research) drug Vectibix for the treatment of advanced colorectal cancer. Vectibix, known chemically as panitumumab, was approved for use in patients whose colon cancer has spread after chemotherapy has failed. << I had just bought back my covered calls yesterday figuring this was likely, but bit of uncertainty regarding the robustness of the data was lingering, so this is nice. Be interesting to see label details. And perhaps even more interesting to see the price of Vectibix.. Cheers, Tuck